SS
BPMC

SBI Securities’s Blueprint Medicines BPMC Stock Holding History

SBI Securities’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5
Closed -$641 – 4200
2025
Q2 		$641 Sell
5
-5
-50% -$519 ﹤0.01% 2859
2025
Q1 		$885 Buy
10
+5
+100% +$488 ﹤0.01% 2640
2024
Q4 		$436 Buy
+5
New +$458 ﹤0.01% 2942

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SBI Securities's BPMC Position: Q3 2025 in Review

SBI Securities sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 5 shares — an estimated $641 sold.

SBI Securities first reported a position in BPMC in Q4 2024 and held it in 3 quarters. The position peaked at $885 in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • SBI Securities reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • SBI Securities sold 5 Blueprint Medicines shares in Q3 2025, an estimated $641.
  • SBI Securities first reported a position in Blueprint Medicines in Q4 2024 and held it in 3 quarters.
  • SBI Securities's Blueprint Medicines position peaked at $885 in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.